United States: Trinity Homecare Settlement: Five False Claims Trends

Last Updated: July 16 2015
Article by Ellyn Sternfield

New York State Attorney General Eric Schneiderman recently announced that his office had reached a $2.5 million settlement in a federal False Claims Act (FCA) case with Trinity HomeCare and its related entities.  The case, filed as a qui tam action in federal district court in the Eastern District of New York, alleged that Trinity's violations of New York's Medicaid regulations in the delivery of hemophilia drugs resulted in its submission of false claims to the New York Medicaid Program, in violation of both the federal and state FCAs.

The Trinity settlement may seem relatively insignificant, especially in comparison to other FCA cases which settled for billions, not millions, of dollars.  But the Trinity case may be more representative of the future of FCA enforcement.  Indeed, there are five current FCA trends evidenced by the Trinity case.

1. FCA Case Pursued and Settled After Federal Government Declination

In the olden days of FCA litigation (meaning five or six years ago), federal government declination often meant the end of the case.  But now a federal declination is often just the first stage of FCA litigation.  As in the Trinity case, more and more FCA cases are being litigated by relators in the absence of federal intervention.

And that is especially so where the allegations involve Medicaid billings and are brought by a relator alleging violation of both the federal and a state FCA.  While the federal government may have declined the Trinity case, the New York Attorney General's Medicaid Fraud Control Unit (MFCU) took it on, launched its own investigation, and apparently was the driving force behind the settlement.

As noted in my recent blog post, FCA settlements without federal government intervention do pose risks for defendants, as evidenced by the Trinity settlement. While the federal government did not object to the settlement terms negotiated by the state MFCU, it also did not provide the defendants with a federal release.  HHS-OIG was not a party to the settlement and so no release from OIG's exclusion authority was provided to the defendants.

2. FCA Case Alleging a Single-State or Regional Billing Scheme

In the past, the majority of litigated FCA cases were brought against national companies and involved allegations of national schemes.  Now, as in Trinity, it is more common to see a FCA case being litigated against a health care provider operating in one state or a specific region.

There are multiple reasons for this trend, including increased FCA experience by government lawyers and the relator's bar, the proliferation of state FCAs, and employees and business associates who are more knowledgeable about the FCA.

But another reason may be the current focus on the pleading specificity required for a FCA action.  In Trinity, the plaintiffs cited to specific New York Medicaid Program preconditions for billing specialty drugs, such as the hemophilia drugs at the heart of the case, including delivery documentation/signature requirements.  The plaintiffs alleged that Trinity's failure to adhere to those requirements meant New York Medicaid should not have been billed, let alone have reimbursed Trinity, for the drugs, rendering the claims false and therefore actionable under the state and federal FCAs.

3. FCA Cases Based on Government Billings for Specialty Drugs

Specialty Drugs are big ticket items, with government health care reimbursements often running thousands of dollars for a single patient's single dose.  So it is not surprising that more and more FCAs are being filed involving government payments for specialty drugs.

In Trinity, the drugs at issue were a handful of hemophilia specialty drugs, which over four and half years accounted for more than $31 million dollars in New York Medicaid payments to Trinity.  The qui tam alleged that Trinity's policy on drug shipment/delivery resulted in unneeded and unused medications being billed to Medicaid. As part of its investigation, the New York MFCU audited Trinity's records for ten of the Medicaid patients and then interviewed the patients and their families, substantiating allegations in relation to nine of those ten patients.

4. FCA Cases Based on Conduct Subject to Prior Warnings/Administrative Actions

Health care billing requirements can be mind-numbingly complex. The red tape involved in distinguishing between different billing and documentation rules for individual government programs can be an attractive defense to a FCA case based on specific requirements for just one of those programs. The plaintiff must be able to establish more than mere negligence by the defendant in failing to follow the regulatory scheme applicable to the billings at issue.

The covered conduct addressed in the Trinity settlement ran from January 2007-September 2011.  The dates chosen were likely no accident:  Trinity's Medicaid billing practices in 2005-2006 had been subject to a prior New York Medicaid Inspector General administrative audit, resulting in an assessment of a Medicaid overpayment in excess of $3 million.  Despite that history, the relator alleged that Trinity managers specifically instructed employees to send/leave Medicaid-covered hemophilia drugs without obtaining the requisite signatures.  Relator also alleged that the problems with adherence to New York Medicaid billing requirements had been reported to Trinity's national sales director of hemophilia services, with no resulting action by management.

5. FCA Cases Involving Multiple Defendants Named in Multiple Complaints

It is increasingly common to see FCA cases that name multiple defendants and for there to be multiple FCA cases pending against the same defendant(s) for similar or related conduct.

The Trinity settlement documents established that Trinity is a New York State pharmacy and home care provider; in 2007 Trinity was acquired by Option Care and later that same year Walgreen Co. acquired Option Care.  At the time of the settlement, Trinity operated as a wholly owned subsidiary of Walgreen.  Trinity, Option care and Walgreen were all named in the Trinity case and signed off on the $2.5 million settlement.

But the $2.5 Trinity settlement is not the end of companies' involvement with the New York MFCU.  Several days after announcing the $2.5 settlement, Attorney General Schneiderman announced that his MFCU has reached a separate settlement with the same companies out of a separate qui tam filed in the federal district court in the Southern District of New York that involved the operations of Trinity.  In that separate case pending in a separate court, the relator alleged that Trinity had submitted false Medicaid claims for a specialty drug used to treat premature infants at risk for lung disease.  The drug at issue was reimbursed by Medicaid at up to $2,000 per vial.   According to the Attorney General's press release, when the new qui tam was filed, it immediately caught his staff's attention because of the ongoing investigation involving Trinity's billing for hemophilia drugs.

According to the settlement documents, through its investigation related to hemophilia drugs, the MFCU had learned of existing concerns about Trinity's practices related to this pediatric specialty drug.  Then the qui tam was filed by a physician who alleged that Trinity submitted Medicaid claims for this drug when it had not actually been prescribed by the infant's treating physician: Trinity allegedly inserted the name of a neonatal unit physician or other physician as prescriber, including the relator, when that physician had not treated the child at issue.  While the federal government again declined the qui tam, the state took it on and the defendants again settled with New York for just under $22.5 million.   And again, the federal government is not a signatory to the settlement.

Closing

While there still may be an occasional mega-FCA settlement out there, I expect to see many more of these smaller, state-specific FCA cases being filed and pursued, especially if the case involves some of the same factors present in the Trinity case.  And I expect these cases to continue to move forward even when the federal government declines to intervene in the case.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Ellyn Sternfield
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions